Bayer to Buy Vitamin Company Care/Of for $225 Million
(Bloomberg) -- Bayer AG agreed to buy online vitamin and health supplement company Care/of as the German drugmaker aims to expand its nutrition business.
Bayer is acquiring 70% of the four-year-old business in a transaction that values the company at $225 million, according to a person familiar with the matter. Bayer will have an option to buy the rest by 2022, said the person, who asked to not be identified because the terms of the transaction are private.
The German company is seeking growth from new sources in an effort to move on from a $1.6 billion settlement of litigation over its Essure contraceptive device and an $11 billion deal to resolve cases involving its Roundup weedkiller.
Bayer shares rose as much as 1% Tuesday morning in Frankfurt.
The deal is an “important milestone” for both Bayer and Care/of, said Bayer spokesman Dan Childs, who declined to comment on the terms.
“We believe this model and product type has the ability to expand into traditional retail channels as we aim to reach new consumers,” Childs said in a statement. “Together we plan to grow the Care/of business across new channels, new categories and new markets to deliver even more personalized nutrition.”
A representative for Care/of didn't immediately respond to a request for comment.
Care/of was founded in New York City by Craig Elbert and Akash Shah in 2016, according to its website. The company sells vitamin subscriptions as well as accessories such as reusable drink bottles and coffee cups. It was valued at $156 million in 2018 after raising funds from investors including Goldman Sachs Group Inc.'s venture capital unit.
The purchase comes after Bayer agreed to buy British women's health biotech Kandy Therapeutics Ltd. in a $875 million deal this month.
The transaction is another example of investors' increasing appetite for digital-health businesses in the midst of a global pandemic. Telemedicine company Hims Inc., which sells wellness and health-care products, is in talks to go public through a merger with blank-check company Oaktree Acquisition Corp. Earlier this month, Teladoc Health Inc. said it was acquiring Livongo Health Inc. for about $18.5 billion.
©2020 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.